We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
-10.5%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$300M
AUM Growth
-$19.2M
Cap. Flow
+$40.1M
Cap. Flow %
13.37%
Top 10 Hldgs %
79.17%
Holding
32
New
7
Increased
1
Reduced
2
Closed
6

Top Buys

1
ALPN
Alpine Immune Sciences Inc
ALPN
+$82.6M
2
ROIV icon
Roivant Sciences
ROIV
+$16.5M
3
LNTH icon
Lantheus
LNTH
+$10.4M
4
AURA icon
Aura Biosciences
AURA
+$9.36M
5
IMGN
Immunogen Inc
IMGN
+$6.92M

Top Sells

1
ALP.PRN
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
+$69M
2
APGN
Apexigen, Inc. Common Stock
APGN
+$814K
3
ACET icon
Adicet Bio
ACET
+$674K
4
SLRN
ACELYRIN
SLRN
+$130K
5
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$92.5K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
1
DELISTED
Alpine Immune Sciences Inc
ALPN
$76.8M 25.63%
+6,708,288
New +$82.6M
ZNTL icon
2
Zentalis Pharmaceuticals
ZNTL
$325M
$42.1M 14.06%
2,099,583
– –
AURA icon
3
Aura Biosciences
AURA
$713M
$18.2M 6.09%
1,163,123
+869,790
+297% +$9.36M
ROIV icon
4
Roivant Sciences
ROIV
$24.4B
$17M 5.69%
+1,459,700
New +$16.5M
SLRN
5
DELISTED
ACELYRIN
SLRN
$15.7M 5.26%
1,548,317
-6,100
-0.4% -$130K
RCUS icon
6
Arcus Biosciences
RCUS
$3.35B
$15.6M 5.21%
869,790
– –
TXG icon
7
10x Genomics
TXG
$5.65B
$14.8M 4.95%
359,554
– –
ARGX icon
8
argenx
ARGX
$53.7B
$13.5M 4.5%
27,429
– –
PACB icon
9
Pacific Biosciences
PACB
$463M
$12.2M 4.08%
1,463,872
– –
ILMN icon
10
Illumina
ILMN
$28.8B
$11.1M 3.7%
83,123
– –
LNTH icon
11
Lantheus
LNTH
$6.84B
$9.88M 3.3%
+142,196
New +$10.4M
HZNP
12
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.13M 3.05%
78,900
– –
PHAT icon
13
Phathom Pharmaceuticals
PHAT
$875M
$8.81M 2.94%
850,000
– –
IMGN
14
DELISTED
Immunogen Inc
IMGN
$6.6M 2.2%
+415,880
New +$6.92M
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$4.88M 1.63%
23,014
– –
HLTH
16
DELISTED
Cue Health Inc. Common Stock
HLTH
$3.97M 1.32%
8,980,909
– –
BYSI icon
17
BeyondSpring
BYSI
$52.6M
$3.97M 1.32%
+4,958,143
New +$4.85M
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$3.59M 1.2%
714,285
– –
EQ icon
19
Equillium
EQ
$158M
$3.29M 1.1%
4,447,308
– –
WHWK
20
Whitehawk Therapeutics
WHWK
$192M
$2.55M 0.85%
526,329
– –
ATRC icon
21
AtriCure
ATRC
$1.8B
$2.03M 0.68%
+46,259
New +$2.26M
SCYX icon
22
SCYNEXIS
SCYX
$44.5M
$1.27M 0.42%
69,444
– –
MRSN
23
DELISTED
Mersana Therapeutics
MRSN
$1.15M 0.38%
36,171
– –
PYXS icon
24
Pyxis Oncology
PYXS
$141M
$650K 0.22%
+326,810
New +$757K
WGS icon
25
GeneDx Holdings
WGS
$1.83B
$377K 0.13%
103,604
– –
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q3 2023 Portfolio in Review

As of Q3 2023, Decheng Capital Management III (Cayman) held 32 positions worth $300M, down 6% from $319M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Decheng Capital Management III (Cayman) deployed $40.1M of net new capital in Q3 2023, opening 7 new positions and adding to 1 existing holding. Its largest new stake was Alpine Immune Sciences Inc: 6,708,288 shares worth $76.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 71% a quarter earlier.

On the sell side, the largest reduction was Adicet Bio, an estimated $674K trimmed.

  • Decheng Capital Management III (Cayman)'s largest Q3 2023 buy was Alpine Immune Sciences Inc: 6,708,288 shares worth $76.8M.
  • Decheng Capital Management III (Cayman) added most to Aura Biosciences in Q3 2023, an estimated $9.36M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q3 2023 reduction was Adicet Bio, cutting an estimated $674K.
  • Decheng Capital Management III (Cayman) fully exited Alabama Power Co 5.20% CL-A PRF in Q3 2023, selling an estimated $69M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 79% of its $300M portfolio in Q3 2023.
  • Decheng Capital Management III (Cayman) opened 7 new positions and closed 6 in Q3 2023.
  • Decheng Capital Management III (Cayman)'s portfolio value fell 6% quarter-over-quarter to $300M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.